TABLE 2.
Characterization of splenocyte populations in transgenic micea
| Strain | Mean ± SEM (n = 3–6 mice/group)
|
||||
|---|---|---|---|---|---|
| Total splenocytes (106) | Positive cells/spleen (106)
|
||||
| CD4+ | γδ+ | IA+ | IE+ | ||
| C57BL/6 | 98.3 ± 5.5 | 10.88 ± 2.7 (11b) | 4.0 ± 2.5 (4) | 53.8 ± 10.4 (55) | 0 ± 0 |
| ABo | 77.6 ± 16.2 | 1.5 ± 0.48c (2) | 1.7 ± 0.8 (2) | 5.5 ± 1.2c (7) | 0 ± 0 |
| ABoEα | 48.1 ± 9.2c | 6.0 ± 0.70c (12) | 2.6 ± 1.3 (5) | 4.3 ± 1.2c (9) | 23.6 ± 3.9c (49) |
| Bl.Tg.Eα | |||||
| Untreated | 59.9 ± 18.4c | 8.2 ± 2.1 (14) | 8.8 ± 3.9 (15) | 43.2 ± 8.6 (72) | 38.9 ± 4.6c (65) |
| Treated with anti-γδ TcR | 71.1 ± 10.3 | 10.6 ± 1.1 (15) | 0.5 ± 0.1cd (0.1) | ND | ND |
a
Spleen cells from individual animals infected 7 days earlier with 5 × 104 PFU of CVB3 were treated with RBC lysing solution (Sigma) and counted by trypan blue exclusion, and aliquots of the cells were stained for the cell surface markers as described in Materials and Methods. ND, not determined.
b
Percentage of total splenocytes positive for the marker.
c
Total cells per spleen differ from C57BL/6 group at P ≤ 0.05 by Wilcoxon ranked score.
d
Anti-γδ treatment significantly reduced total γδ+ T cells in spleens of Bl.Tg.Eα mice compared to isotype antibody-treated control animals of the same strain (P ≤ 0.05).